Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
NCT ID: NCT00059813
Last Updated: 2013-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
41 participants
INTERVENTIONAL
2003-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To estimate the objective response rate of metastatic renal cancer to the combination of G3139 plus α-Interferon (α-IFN).
SECONDARY OBJECTIVES:
I. To further assess the clinical toxicity of this combination. II. To evaluate the impact of G3139 plus α-IFN on molecular targets involved in the regulation of apoptosis in tumor cells and lymphocytes.
III. To evaluate the pharmacokinetics of G3139 when given with α-IFN at this dose and schedule.
IV. To evaluate the potential toxicity of this combination on cells of the immune system.
OUTLINE: This is a multicenter study.
Patients receive oblimersen IV continuously on days 1-7 and interferon alfa subcutaneously on days 4, 6, 8, 10, and 12 of course 1 and on days 1, 3, 5, 8, 10, and 12 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete remission (CR) receive an additional 2 courses past CR.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 21-41 patients will be accrued for this study within 20-24 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (recombinant interferon alfa, oblimersen sodium)
Patients receive oblimersen IV continuously on days 1-7 and interferon alfa subcutaneously on days 4, 6, 8, 10, and 12 of course 1 and on days 1, 3, 5, 8, 10, and 12 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive an additional 2 courses past CR.
recombinant interferon alfa
Given SC
oblimersen sodium
Given IV
pharmacological study
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
recombinant interferon alfa
Given SC
oblimersen sodium
Given IV
pharmacological study
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Performance status 0-2 (SWOG), life expectancy \> 3 months
* Prior radiation must have been completed \> 4 weeks before enrollment, with measurable disease outside of the radiation port
* WBC \> 3500/μl
* Absolute neutrophil count \> 1500/μl
* Platelets \> 100,000/μl
* Transaminases \< 2 x institutional upper limit of normal
* Serum bilirubin \< 1.5 x institutional upper limit of normal (if Gilbert's, up to 2 x upper limit)
* Serum alkaline phosphatase \< 2.5 x institutional upper limit of normal
* Patients with hepatic metastases may have 50% higher levels of all the above-listed parameters
* Serum creatinine \< 1.5 x institutional upper limit of normal
* Patients with active or recently-treated autoimmune disease are excluded, as are patients currently receiving or expected to require corticosteroid therapy
* Prior malignancy is limited to adequately treated non-melanoma skin cancer, cervical carcinoma-in-situ, or any other malignancy for which the patient has been disease-free for at least 5 years
* Because the effects of G3139 on the unborn fetus or newborn infant are unknown, pregnant or lactating women are excluded, and patients with reproductive potential must agree to use a medically-acceptable form of birth control
* Patients must have fully recovered from the effects of any prior surgery or medical illness such as infection; those with psychosocial problems that might compromise safety or protocol compliance are excluded
* Central venous access is required
* Patients may have received up to two prior biological therapy regimens, excluding exposure to either of the therapy agents and patients may have had no more than one prior chemotherapy regimen; full recovery from all toxicities must have occurred; for high-dose IL-2, at least 8 weeks must have elapsed since prior treatment
* Written, voluntary informed consent
* Previous chemotherapy must have been completed at least 3 weeks before treatment under this protocol can be initiated
* Patients with a history of brain metastases, or who are currently being treated, or have untreated brain metastases, are not eligible; Note: if patient received steroid therapy, at least three weeks must have elapsed prior to entry on this protocol
* Patients must have normal baseline PT/PTT; Note: For those patients taking low dose coumadin (e.g., as prophylaxis for a venous access device) and INR of up to 1.5 is allowed
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kim Margolin
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope
Duarte, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2012-02828
Identifier Type: REGISTRY
Identifier Source: secondary_id
PHII-42
Identifier Type: OTHER
Identifier Source: secondary_id
5828
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-02828
Identifier Type: -
Identifier Source: org_study_id